Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma

SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response

(2021) Michael Markus Bonelli et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases

(2021) Robert Spiera et al.   ANNALS OF THE RHEUMATIC DISEASES

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

(2021) Fulvia Pimpinelli et al.   Journal of Hematology & Oncology

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

(2021) Delphine Planas et al.   NATURE MEDICINE

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

(2021) Alfredo Addeo et al.   CANCER CELL

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

(2021) Oliver Van Oekelen et al.   CANCER CELL

Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors

(2021) Evangelos Terpos et al.   Journal of Hematology & Oncology

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

(2021) Delphine Planas et al.   NATURE

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

(2021) Joana Barros-Martins et al.   NATURE MEDICINE

A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations

(2020) Ludivine Grzelak et al.   Science Translational Medicine